Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 42 entries
View as:

A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients with CAIX-positive Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06840548 Org: User:
Start: 02/28/25 End: 12/31/25 Due: 12/31/26

A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT02957032 Org: User:
Start: 04/13/16 End: 09/29/23 Due: 09/29/24

F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02054884 Org: User:
Start: 10/25/13 End: 12/15/17 Due: 12/15/18

A Randomized, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of F8IL10 (Dekavil) in Patients With Active RA Receiving MTX

Phase: N/A Priority: Normal
NCT ID: NCT02270632 Org: User:
Start: 10/01/14 End: 06/08/23 Due: 06/08/24

Phase 1 Dose-finding Study of L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion (ILP) in Subjects With Intransit Stage III/IV Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01213732 Org: User:
Start: 10/31/08 End: 09/30/11 Due: 09/30/12

A Dose Finding and Efficacy Study of the Tumour Targeting Human 131I-F16SIP Monoclonal Antibody in Patients With Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01240720 Org: User:
Start: 09/30/08 End: 04/30/13 Due: 04/30/14

Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA)

Phase: N/A Priority: Normal
NCT ID: NCT03420014 Org: User:
Start: 12/27/18 End: 12/31/25 Due: 12/31/26

Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT04362722 Org: User:
Start: 09/02/20 End: 09/30/24 Due: 09/30/25

Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients

Phase: N/A Priority: Normal
NCT ID: NCT03567889 Org: User:
Start: 09/20/18 End: 06/30/26 Due: 06/30/27

A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression

Phase: N/A Priority: Normal
NCT ID: NCT04573192 Org: User:
Start: 02/19/21 End: 12/31/25 Due: 12/31/26

A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours

Phase: N/A Priority: Normal
NCT ID: NCT01058538 Org: User:
Start: 11/30/05 End: 11/30/09 Due: 11/30/10

L19IL2/L19TNF in Skin Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT05329792 Org: User:
Start: 03/09/23 End: 12/31/24 Due: 12/31/25

A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT02076646 Org: User:
Start: 07/31/13 End: 06/30/22 Due: 06/30/23

Combination Therapy of F8IL10 and Methotrexate in Rheumatoid Arthritis Patients

Phase: N/A Priority: Normal
NCT ID: NCT02076659 Org: User:
Start: 09/30/11 End: 04/13/17 Due: 04/13/18

Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse

Phase: N/A Priority: Normal
NCT ID: NCT03779230 Org: User:
Start: 05/31/19 End: 06/27/23 Due: 06/27/24

Dose Finding Study of L19TNF and Doxorubicin in Patients With STS

Phase: N/A Priority: Normal
NCT ID: NCT04032964 Org: User:
Start: 09/05/19 End: 12/31/24 Due: 12/31/25

Radioimmunotherapy With 131I-L19SIP in Patients With Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01242943 Org: User:
Start: 11/30/08 End: 05/31/11 Due: 05/31/12

Neoadjuvant L19IL2/L19TNF- Pivotal Study

Phase: N/A Priority: Normal
NCT ID: NCT02938299 Org: User:
Start: 07/01/16 End: 12/31/28 Due: 12/31/29

L19TNFα in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01253837 Org: User:
Start: 09/30/07 End: 09/30/11 Due: 09/30/12

Safety and Early Signs of Efficacy of IL12-L19L19.

Phase: N/A Priority: Normal
NCT ID: NCT04471987 Org: User:
Start: 07/01/20 End: 12/31/25 Due: 12/31/26

131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiation in Patients With Multiple Brain Metastases From Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01125085 Org: User:
Start: 10/31/09 End: 06/30/13 Due: 06/30/14

Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression

Phase: N/A Priority: Normal
NCT ID: NCT05304663 Org: User:
Start: 06/01/22 End: 12/31/24 Due: 12/31/25

A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT04650984 Org: User:
Start: 11/29/17 End: 12/31/25 Due: 12/31/26

Intratumoral Application of L19IL2 in Patients With Malignant Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01253096 Org: User:
Start: 04/30/10 End: 09/30/13 Due: 09/30/14

Trial to Find and Investigate a Safe Dose of F16IL2 and BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT03207191 Org: User:
Start: 12/02/16 End: 03/26/20 Due: 03/26/21